Why La Jolla (LJPC) Is Surging Today

NEW YORK (TheStreet) -- La Jolla Pharmaceutical (LJPC) stock is seeing an astronomical rise on Tuesday on the news that the clinical trial for its galectin inhibitor -- used to treat chronic kidney disease -- was a success.

CEO George Tidmarsh said, "We are obviously delighted with the results. We hope to use these results as a platform for further investigation not only in chronic kidney disease but also in other diseases where tissue fibrosis plays a central role."

The stock is up $7.43, or 68%, and was trading at $18.33 by early afternoon.

In-Depth Analysis:  LJPC Clinical Trials

While investors are excited about the potential of a drug that can successfully treat the 50 million Americans who suffer from kidney disease, La Jolla's clinical trials is not without its detractors. Concerns include insufficient time allotted for observation and the ineffectiveness of higher doses of the drug on patients.

The Street's Adam Feuerstein has been covering La Jolla in depth for months and has a unique take on the news.

Read Adam's Take:  La Jolla's Kidney Drug Is Statistical Noise

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

LJPC ChartLJPC data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists